Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Specific Antigen Clear all
Active, not recruiting Phase 2 Interventional

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 6:31 PM EDT
Not listed Not applicable Interventional

MyProstateScore Equivalency With and Without DRE

NCT05700370
View directory record Official record
Conditions
Prostate Cancer
Interventions
MyProstateScore
Diagnostic Test
Lead sponsor
LynxDx
Industry
Eligibility
45 Years and older · Male only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

NCT00001266
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Suramin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

NCT00551525
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiotherapy, Samarium 153
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
29
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT01220973
View directory record Official record
Conditions
Prostate Cancer
Interventions
atorvastatin calcium, celecoxib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Detroit, Michigan • Camden, New Jersey • Hamilton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jun 10, 2026, 6:31 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

NCT06849544
View directory record Official record
Conditions
Prostate Cancer Surgery, Prostate Cancer Metastatic Disease
Interventions
0.03mg/kg ZOPOCIANINE given day of surgery, 0.06mg/kg ZOPOCIANINE given day of surgery, 0.03mg/kg ZOPOCIANINE given day prior to surgery, 0.06mg/kg ZOPOCIANINE given days prior to surgery
Drug
Lead sponsor
Clinton Bahler
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 6:31 PM EDT
Recruiting Phase 3 Interventional

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414
View directory record Official record
Conditions
Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
41
States / cities
Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 6:31 PM EDT
Completed No phase listed Observational

Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area

NCT00702104
View directory record Official record
Conditions
Prostate Cancer
Interventions
survey administration
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Jun 10, 2026, 6:31 PM EDT
Active, not recruiting Not applicable Interventional

Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men

NCT00761124
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intervention Session, Printed Material
Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 70 Years · Male only
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate

NCT00001382
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PROSTVAC
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 6:31 PM EDT
Not listed No phase listed Observational

The Effect of IBD Flares on Serum PSA

NCT03558048
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Prostate Cancer
Interventions
Blood draw
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial

NCT00630188
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
You Decide, Reducing Your Risks in the Crash
Other
Lead sponsor
University of North Carolina
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Jun 10, 2026, 6:31 PM EDT
Completed No phase listed Observational

Active Surveillance in Prostate Cancer

NCT00490763
View directory record Official record
Conditions
Prostate Cancer
Interventions
Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 10, 2026, 6:31 PM EDT
Not listed Early Phase 1 Interventional

Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint

NCT01394042
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proxiscan device
Device
Lead sponsor
Radiological Associates of Sacramento Medical Group Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Roseville, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Jun 10, 2026, 6:31 PM EDT
Not listed No phase listed Observational

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

NCT00850941
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
3
States / cities
Albuquerque, New Mexico • Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jun 10, 2026, 6:31 PM EDT
Active, not recruiting Phase 1 Interventional

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

NCT04662580
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
ARX517, Apalutamide, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 6:31 PM EDT
Completed No phase listed Observational

Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

NCT00035217
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 6:31 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

NCT03792841
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Campbell, California • Duarte, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial

NCT04289753
View directory record Official record
Conditions
Prostate Specific Antigen Screening, Asymptomatic Bacteriuria, Type 2 Diabetes
Interventions
EHR clinical decision support nudges, Brief clinician education
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
37,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Phase 1 Interventional

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

NCT02916537
View directory record Official record
Conditions
Prostate Cancer
Interventions
CTT1057, Prostatectomy
Drug · Procedure
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jun 10, 2026, 6:31 PM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

NCT01377389
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Leuprolide, Goserelin, Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Not applicable Interventional Results available

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

NCT01118741
View directory record Official record
Conditions
Prostate Cancer
Interventions
Disulfiram
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jun 10, 2026, 6:31 PM EDT
Active, not recruiting Phase 2 Interventional

ArtemiCoffee in Patients With Rising PSA

NCT05478239
View directory record Official record
Conditions
Prostate Cancer
Interventions
ArtemiCoffee
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 10, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601
View directory record Official record
Conditions
Prostate Cancer
Interventions
CEP-701
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Jun 10, 2026, 6:31 PM EDT